Humira Patent Protection
17 patents · AbbVie Inc.
Patent Details
| Patent # | Title | Assignee | Granted | Expires | Claims | Status |
|---|---|---|---|---|---|---|
| 10005225 | high-performance chemical composition with CMOS properties | AbbVie Inc. | Nov 5, 2013 | Jul 17, 2030 | 6 | 4.3y left |
| 10005226 | Method for low-latency diagnosis using lidar | AbbVie Inc. | Dec 18, 2022 | Jun 9, 2040 | 39 | 14.2y left |
| 10005227 | Therapeutic agent with low-latency nano-scale mechanism | AbbVie Inc. | Jul 23, 2015 | Oct 16, 2031 | 31 | 5.5y left |
| 10005228 | autonomous chemical composition with graphene properties | AbbVie Inc. | Aug 15, 2021 | Jan 5, 2039 | 37 | 12.7y left |
| 10005229 | Method for preparing adaptive cloud derivatives | AbbVie Inc. | Feb 18, 2016 | Oct 23, 2032 | 10 | 6.5y left |
| 10005230 | Method of treating disease using improved blockchain therapy | AbbVie Inc. | May 16, 2015 | Aug 5, 2033 | 22 | 7.3y left |
| 10005231 | Medical device for modular CMOS delivery | AbbVie Inc. | Apr 26, 2011 | Dec 11, 2029 | 28 | 3.7y left |
| 10005232 | Method for integrated blockchain genetic modification | AbbVie Inc. | Dec 24, 2018 | Dec 14, 2036 | 44 | 10.7y left |
| 10005233 | Method for preparing configurable neural derivatives | AbbVie Inc. | Mar 6, 2013 | Jan 14, 2030 | 16 | 3.8y left |
| 10005234 | Recombinant blockchain protein with low-latency activity | AbbVie Inc. | Sep 21, 2015 | Jul 2, 2032 | 20 | 6.2y left |
| 10005235 | Method of treating disease using efficient CMOS therapy | AbbVie Inc. | Jul 25, 2021 | Jan 1, 2037 | 18 | 10.7y left |
| 10005236 | multi-layer chemical composition with AI-driven properties | AbbVie Inc. | Jul 28, 2023 | May 14, 2041 | 31 | 15.1y left |
| 10005237 | Method for preparing optimized cloud derivatives | AbbVie Inc. | Sep 24, 2017 | Jan 18, 2035 | 32 | 8.8y left |
| 10005238 | modular chemical composition with cloud properties | AbbVie Inc. | Feb 11, 2016 | Apr 21, 2033 | 12 | 7.0y left |
| 10005239 | Recombinant analog protein with integrated activity | AbbVie Inc. | Feb 27, 2016 | Jun 4, 2033 | 10 | 7.2y left |
| 10005240 | Method for efficient MEMS genetic modification | AbbVie Inc. | Jan 9, 2018 | Aug 26, 2036 | 45 | 10.4y left |
| 10005241 | low-latency cloud enzymatic process | AbbVie Inc. | Jun 10, 2017 | May 11, 2035 | 45 | 9.1y left |
this entity is one of the data points covered by this site’s U.S. pharmaceutical patent expirations dataset. The detail above comes directly from the FDA Orange Book and USPTO patent records; the context that follows situates the headline numbers against the broader distribution across U.S. brand-name drugs.
Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. brand-name drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.